TCT 2025 | INVEST-CTO: Effectiveness and Safety of a Planned Investment Procedure in High-Risk CTO PCI

The success rate of percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains lower than for non-occlusive lesions, especially in complex CTOs. Furthermore, complications increase in prolonged and unsuccessful procedures, leading many CTO patients to be less frequently offered percutaneous revascularization.

When the initial attempt fails, a balloon dilation aimed at modifying the CTO is often performed, a strategy that has retrospectively shown to improve success rates in subsequent procedures.

The aim of the INVEST-CTO study was to determine whether, in patients with highly complex anatomical CTOs, a planned two-stage strategy—initial modification followed by a second procedure for complete recanalization—results in higher procedural success and improved safety.

The primary endpoint (PEP) was procedural success, defined as technical success without major adverse cardiac events (MACE: death, myocardial infarction, or clinically driven revascularization of the treated vessel). The secondary endpoint (SEP) was a 30-day safety composite.

Read also: TCT 2025 | INFINITY–SWEDEHEART: Long-Term Outcomes of the Bioadaptive Coronary Implant Versus Drug-Eluting Stent.

A total of 153 patients were analyzed, with a mean age of 66 years, predominantly male. The most common presentation was stable coronary artery disease. The mean J-CTO score was 4, indicating high complexity. The right coronary artery was most frequently involved (66%), followed by the left anterior descending (16%) and the circumflex (16%).

Regarding the PEP, the procedural success rate was 86.7% (95% CI 80.3–91.7; p < 0.05). For the SEP, the 30-day composite adverse event rate was 4.6%, suggesting a favorable safety profile.

Conclusion

A planned two-stage strategy for complex CTO intervention proved safe and effective. Initial modification of the CTO should be considered an early and rational approach in high-risk CTOs, with the potential to increase success rates and reduce complications.

Reference: Anja Øksnes, MD. TCT 2025.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Andrés Rodríguez
Dr. Andrés Rodríguez
Member of the Editorial Board of solaci.org

More articles by this author

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...